SCHEMBL8487183

SCHEMBL8487183

COC(=O)C[C@H]1c2ccccc2C2CN(C(=O)CCCNc3ccccn3)CCC21

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 9/20 0.42
ITGAV P06756 9/20 0.42
ITGA2B P08514 5/20 0.42
F2 P00734 1/20 0.39
NOS2 P35228 1/20 0.39
ITGB1 P05556 2/20 0.38
DPP4 P27487 2/20 0.38
ITGB5 P18084 3/20 0.38
GRIN2B Q13224 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
DRD2 P14416 1/20 0.35
ADRA1A P35348 1/20 0.35
DRD3 P35462 1/20 0.35
ALDH1A1 P00352 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14195947 1.00 ITGB3 (0.42) ITGB3ITGAVITGA2BF2NOS2
SCHEMBL14195948 1.00 ITGB3 (0.42) ITGB3ITGAVITGA2BF2NOS2
SCHEMBL14195945 0.90 ITGB3 (0.48) ITGB3ITGAVITGA2BNOS2ITGB1
SCHEMBL4805768 0.90 ITGB3 (0.48) ITGB3ITGAVITGA2BNOS2ITGB1
SCHEMBL14195949 0.90 ITGB3 (0.48) ITGB3ITGAVITGA2BNOS2ITGB1
SCHEMBL14224073 0.88 ITGB3 (0.43) ITGB3ITGAVITGA2BF2NOS2
SCHEMBL8486338 0.84 NPC1 (0.36) NOS2GRIN2BNPC1RAB9AALDH1A1
SCHEMBL8485605 0.79 ALDH1A1 (0.34) NPC1RAB9AADRA1AALDH1A1SMN1; SMN2
SCHEMBL8487967 0.76 ITGB3 (0.42) ITGB3ITGAVITGA2BDPP4ALDH1A1
SCHEMBL4720020 0.76 ITGB3 (0.46) ITGB3ITGAVITGA2BNOS2ITGB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506779-B1 (3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-acetic acid derivatives and related tricyclic indanyls as alphaVbeta3 and alphaVbeta5 integrin inhibitors for the treatment of cancer and unstable angina JANSSEN PHARMACEUTICA NV (BE) 2006-07-12 EP disclosed